Literature DB >> 16552171

CDK inhibitor targets: a hit or miss proposition?: cyclin-dependent kinase inhibitors kill tumor cells by downregulation of anti-apoptotic proteins.

Yun Dai1, Steven Grant.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16552171     DOI： 10.4161/cbt.5.2.2568

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  3 in total

1.  Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation.

Authors:  L Wang; L Sun; J Huang; M Jiang
Journal:  Cell Prolif       Date:  2011-06       Impact factor: 6.831

2.  Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor.

Authors:  Jinesh Gheeya; Peter Johansson; Qing-Rong Chen; Thomas Dexheimer; Belhu Metaferia; Young K Song; Jun S Wei; Jianbin He; Yves Pommier; Javed Khan
Journal:  Cancer Lett       Date:  2010-02-04       Impact factor: 8.679

3.  Analyzing bioactive effects of the minor hop compound xanthohumol C on human breast cancer cells using quantitative proteomics.

Authors:  Simon Roehrer; Verena Stork; Christina Ludwig; Mirjana Minceva; Jürgen Behr
Journal:  PLoS One       Date:  2019-03-15       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.